{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320776906240.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood.v99.9.3083"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/99/9/3083/1682741/h80902003083.pdf"}}],"dc:title":[{"@value":"Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>In this study, we investigated the possibility of selective depletion of donor alloantigen-specific T cells from C57BL/6 (H-2b) mice to prevent graft-versus-host disease (GVHD). These cells were first activated with irradiated BALB/c (H-2d) host spleen cells in a 5-day mixed lymphocyte culture. Following this activation, a photoactive rhodamine derivative called 4,5-dibromorhodamine 123 (TH9402), was added. This compound is selectively retained in the mitochondria of activated host-reactive cells but not tumor- or third-party–specific resting cells. The treated cells were subsequently exposed to visible light (514 nm) to deplete the TH9402-enriched activated host-reactive cells. Treatment with photodynamic cell purging process (PDP) inhibited antihost responses measured by cytotoxic T lymphocytes (CTL) by 93%, and interferon-γ production by 66%. By contrast, anti-BCL1 (BALB/c-origin leukemia/lymphoma) and anti–third-party C3H/HeJ (H-2k) responses were preserved. PDP-treated primed C57BL/6 cells were further tested in vivo. All lethally irradiated BALB/c mice inoculated with BCL1 cells and T-cell–depleted bone marrow cells developed leukemia by day +30, with 50% mortality by 100 days. All mice died of GVHD after addition of 5 × 106untreated primed C57BL/6 cells. However, addition of same numbers of PDP-treated cells allowed 90% of the recipients to survive more than 100 days without detectable BCL1 tumor cells and free of GVHD. Moreover, PDP-treated primed C57BL/6 cells retained the ability to induce GVHD in the third-party C3H/HeJ mice. These data suggest that PDP can selectively deplete host alloantigen-specific T cells for GVHD prevention and immune and antileukemia function preserve.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320776906241","@type":"Researcher","foaf:name":[{"@value":"Benny J. Chen"}],"jpcoar:affiliationName":[{"@value":"From the Bone Marrow Transplantation Program, Duke University Medical Center, Durham, NC."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320776906240","@type":"Researcher","foaf:name":[{"@value":"Xiuyu Cui"}],"jpcoar:affiliationName":[{"@value":"From the Bone Marrow Transplantation Program, Duke University Medical Center, Durham, NC."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320776906243","@type":"Researcher","foaf:name":[{"@value":"Congxiao Liu"}],"jpcoar:affiliationName":[{"@value":"From the Bone Marrow Transplantation Program, Duke University Medical Center, Durham, NC."}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320776906242","@type":"Researcher","foaf:name":[{"@value":"Nelson J. Chao"}],"jpcoar:affiliationName":[{"@value":"From the Bone Marrow Transplantation Program, Duke University Medical Center, Durham, NC."}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"15280020"},{"@type":"PISSN","@value":"00064971"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"2002-05-01","prism:volume":"99","prism:number":"9","prism:startingPage":"3083","prism:endingPage":"3088"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/99/9/3083/1682741/h80902003083.pdf"}],"createdAt":"2002-10-11","modifiedAt":"2024-01-06","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285706475475712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Haploidentical Transplantation for Leukemia"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood.v99.9.3083"},{"@type":"CROSSREF","@value":"10.1007/s11912-010-0113-4_references_DOI_CHXQ71swiW0wMHQqcVUoj3kwpml"}]}